Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

No significant associations between breastfeeding practices and overweight in 8-year-old children.

Bjertnaes AA, Grundt JH, Donkor HM, Juliusson PB, Wentzel-Larsen T, Vaktskjold A, Markestad T, Holten-Andersen MN.

Acta Paediatr. 2019 Jul 12. doi: 10.1111/apa.14937. [Epub ahead of print]

PMID:
31299109
2.

Consumption of energy drinks among adolescents in Norway: a cross-sectional study.

Degirmenci N, Fossum IN, Strand TA, Vaktskjold A, Holten-Andersen MN.

BMC Public Health. 2018 Dec 19;18(1):1391. doi: 10.1186/s12889-018-6236-5.

3.

[An 11-month-year-old girl with repeated respiratory infections].

Holten-Andersen MN, Sulheim D, Indrebø M, Holmström H.

Tidsskr Nor Laegeforen. 2010 Apr 22;130(8):846-8. doi: 10.4045/tidsskr.09.0632. Norwegian.

4.

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry.

Clin Chem. 2008 Dec;54(12):e11-79. doi: 10.1373/clinchem.2008.105601.

5.

Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.

Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA.

Clin Cancer Res. 2006 Dec 1;12(23):7054-8. Epub 2006 Nov 17.

6.

Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.

Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brünner N, Christensen IJ.

Eur J Cancer. 2006 Aug;42(12):1889-96. Epub 2006 Jun 30.

PMID:
16809030
7.

Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer.

Holten-Andersen MN, Brünner N, Nielsen HJ, Christensen IJ, Sørensen NM, Rasmussen AS, Primdahl H, Orntoft T.

Int J Biol Markers. 2006 Jan-Mar;21(1):6-11.

PMID:
16711508
8.

Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.

Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS.

Int J Cancer. 2005 Jan 10;113(2):198-206.

9.

Plasma TIMP-1 in patients with colorectal adenomas: a prospective study.

Holten-Andersen MN, Fenger C, Nielsen HJ, Rasmussen AS, Christensen IJ, Brünner N, Kronborg O.

Eur J Cancer. 2004 Sep;40(14):2159-64.

PMID:
15341992
10.

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA.

Clin Cancer Res. 2004 Apr 1;10(7):2289-98.

11.

Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study.

Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brünner N, Fernebro E; EORTC-Receptor and Biomarker Group.

Eur J Cancer. 2004 Jan;40(1):64-72.

PMID:
14687791
12.

Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.

Jensen MK, Holten-Andersen MN, Riisbro R, de Nully Brown P, Larsen MB, Kjeldsen L, Heickendorff L, Brünner N, Hasselbalch HC.

Eur J Haematol. 2003 Nov;71(5):377-84.

PMID:
14667201
13.

Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay.

Holten-Andersen MN, Schrohl AS, Brünner N, Nielsen HJ, Høgdall CK, Høgdall EV.

Int J Biol Markers. 2003 Jul-Sep;18(3):170-6.

PMID:
14535586
14.
15.

Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.

Nøjgaard C, Johansen JS, Krarup HB, Holten-Andersen M, Møller A, Bendtsen F; Danish Viral Hepatitis Study Group.

Scand J Gastroenterol. 2003 Jun;38(6):659-65.

PMID:
12825876
16.

Tumor markers: from laboratory to clinical utility.

Schrohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J, Brünner N; European Organisation for Research and Treatment of Cancer (EORTC) Receptor and Biomarker Group.

Mol Cell Proteomics. 2003 Jun;2(6):378-87. Epub 2003 Jun 17. Review. No abstract available.

17.

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.

Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN.

Mol Cell Proteomics. 2003 Mar;2(3):164-72. Epub 2003 Apr 2.

18.

Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay.

Holten-Andersen MN, Christensen IJ, Nielsen HJ, Lilja H, Murphy G, Jensen V, Brünner N, Piironen T.

Clin Chem. 2002 Aug;48(8):1305-13.

19.

Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components.

Holten-Andersen MN, Brunner N, Christensen IJ, Jensen V, Nielsen HJ.

Scand J Clin Lab Invest. 2002;62(3):223-30.

PMID:
12088341
20.

Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.

Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sørensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brünner N.

Clin Cancer Res. 2002 Jan;8(1):156-64.

21.

Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease.

Nielsen HJ, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J.

Scand J Gastroenterol. 2001 Mar;36(3):265-9.

PMID:
11305513
22.

High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.

Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brünner N.

Clin Cancer Res. 2000 Nov;6(11):4292-9.

23.

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.

Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, Brünner N, Stephens RW.

Br J Cancer. 1999 May;80(3-4):495-503.

Supplemental Content

Loading ...
Support Center